Physician profile
Mohammad Samara
NPI 1679145460
$1,160.52
in general payments reported to CMS, 2019-2025
20 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.03 · 2023: $125 · 2024: $622 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $208.32 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Neurelis, INC. | $201.18 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $175.47 | 2022-2025 | |
| Genentech USA, INC. | $97.63 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Abbvie INC. | $87.75 | 2024-2025 | |
| Lundbeck LLC | $69.85 | 2023-2025 | Vyepti |
| Tg Therapeutics, INC. | $48.85 | 2025 | |
| Alexion Pharmaceuticals, INC. | $39.30 | 2024 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $33.37 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $31.28 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $21.72 | 2024 | Wainua |
| Otsuka America Pharmaceutical, INC. | $19.00 | 2024 | Nuedexta |
| Emd Serono, INC. | $17.02 | 2025 | |
| Averitas Pharma INC. | $16.40 | 2023 | Qutenza |
| Genzyme Corporation | $16.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $16.26 | 2023 | Epidiolex |
| Merz Pharmaceuticals, LLC | $15.80 | 2025 | Xeomin |
| Lilly USA, LLC | $15.29 | 2024 | Emgality, Reyvow |
| Csl Behring | $15.18 | 2024 | Hizentra |
| Argenx US, INC. | $14.54 | 2024 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Samara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.